PharmaEssentia surpasses enrollment goals in clinical trials for hematology candidate BESREMi
PharmaEssentia USA Corporation, a key player in biopharmaceutical innovation and a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced a significant milestone in the development of ... Read More
Merck to acquire Imago BioSciences to expand blood disorder drugs portfolio
Pharma giant Merck will acquire Imago BioSciences, a Nasdaq-listed clinical stage biopharmaceutical company, for a price of $36 per share in cash, which translates to ... Read More